Bristol Myers Squibb Attracts Investors with Stability
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BMY?
Source: NASDAQ.COM
- Price Stability: Bristol Myers Squibb's stock exhibits low volatility with a beta of just 0.2, demonstrating its resilience during market fluctuations, which attracts investors seeking stable returns.
- Dividend Growth: The company has increased its dividend for 17 consecutive years, currently yielding 4.2%, which not only boosts investor confidence but also provides a steady cash flow, further solidifying its market position.
- Sales Forecast Decline: Although total revenue is expected to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, the growth segment's sales rose from $22.6 billion to $26.4 billion, partially offsetting the decline in legacy portfolio revenue.
- Market Reaction Uncertainty: With slowing revenue, the market's reaction to the Q1 2026 earnings report remains uncertain, prompting investors to carefully assess future investment risks and opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 59.020
Low
37.00
Averages
55.86
High
68.00
Current: 59.020
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Stock Rises Over 20%
- Sales Outlook Decline: Bristol Myers Squibb anticipates total revenue to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, indicating vulnerability in the face of market challenges that may impact investor confidence.
- Strong Growth Segment Performance: Despite declining sales from its legacy portfolio, Bristol's growth segment achieved sales of $26.4 billion in 2025, up from $22.6 billion in 2024, demonstrating positive progress in new product development and offsetting legacy revenue declines.
- Dividend Appeal: The company currently offers a dividend yield of 4.26% and has increased its dividend for 17 consecutive years, making it attractive to investors seeking low-volatility investments and enhancing its appeal in uncertain markets.
- Low Volatility Advantage: With a beta of only 0.2, Bristol Myers Squibb exhibits significant price stability relative to market fluctuations, making its stock an ideal choice for long-term investment despite potential market volatility.
See More
Bristol Myers Squibb Attracts Investors with Stability
- Price Stability: Bristol Myers Squibb's stock exhibits low volatility with a beta of just 0.2, demonstrating its resilience during market fluctuations, which attracts investors seeking stable returns.
- Dividend Growth: The company has increased its dividend for 17 consecutive years, currently yielding 4.2%, which not only boosts investor confidence but also provides a steady cash flow, further solidifying its market position.
- Sales Forecast Decline: Although total revenue is expected to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, the growth segment's sales rose from $22.6 billion to $26.4 billion, partially offsetting the decline in legacy portfolio revenue.
- Market Reaction Uncertainty: With slowing revenue, the market's reaction to the Q1 2026 earnings report remains uncertain, prompting investors to carefully assess future investment risks and opportunities.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
Bristol Myers Squibb Stock Rises Over 20%
- Sales Outlook Decline: Bristol Myers Squibb anticipates total revenue to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, indicating vulnerability in the face of market challenges that may impact investor confidence.
- Strong Growth Segment Performance: Despite declining sales from its legacy portfolio, Bristol's growth segment achieved sales of $26.4 billion in 2025, up from $22.6 billion in 2024, demonstrating positive progress in new product development and offsetting legacy revenue declines.
- Dividend Appeal: The company currently offers a dividend yield of 4.26% and has increased its dividend for 17 consecutive years, making it attractive to investors seeking low-volatility investments and enhancing its appeal in uncertain markets.
- Low Volatility Advantage: With a beta of only 0.2, Bristol Myers Squibb exhibits significant price stability relative to market fluctuations, making its stock an ideal choice for long-term investment despite potential market volatility.
See More
Bristol Myers Squibb Attracts Investors with Stability
- Price Stability: Bristol Myers Squibb's stock exhibits low volatility with a beta of just 0.2, demonstrating its resilience during market fluctuations, which attracts investors seeking stable returns.
- Dividend Growth: The company has increased its dividend for 17 consecutive years, currently yielding 4.2%, which not only boosts investor confidence but also provides a steady cash flow, further solidifying its market position.
- Sales Forecast Decline: Although total revenue is expected to range between $46 billion and $47.5 billion in 2026, down from $48.2 billion in 2025, the growth segment's sales rose from $22.6 billion to $26.4 billion, partially offsetting the decline in legacy portfolio revenue.
- Market Reaction Uncertainty: With slowing revenue, the market's reaction to the Q1 2026 earnings report remains uncertain, prompting investors to carefully assess future investment risks and opportunities.
See More
Market Capital Flow Issues Impact Healthcare Stocks
- Healthcare Stocks Hit Hard: Despite strong quarterly results from companies like Thermo Fisher and Danaher, the lack of investor confidence in the healthcare sector has led to significant stock declines, indicating a panic among investors regarding healthcare equities.
- Capital Flow Concentration: Market funds are primarily directed towards stocks tied to data center construction, resulting in persistent selling pressure on healthcare stocks such as Abbott Labs and Cardinal Health, reflecting a risk-averse sentiment among investors towards the healthcare industry.
- IPO Market Impact: Upcoming IPOs like SpaceX are likely to attract substantial capital, further weakening healthcare stock performance, reminiscent of the capital concentration seen during the internet bubble in 1999, which could lead to further declines in healthcare stock P/E ratios.
- Key Earnings Reports from Tech Giants: The upcoming earnings reports from Alphabet, Amazon, Meta, and Microsoft will be crucial; if two of these companies perform well, it may boost market sentiment, whereas poor results could exacerbate downward pressure on healthcare stocks.
See More
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
